Biologics Contract Development Market Likely to Reach Beyond $11.2 Billion by 2027

07/dic/2020 11:13:41 Grand View Research Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The global biologics contract development market size is expected to reach USD 11.2 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.8% over the forecast period. The market comprises of organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications including drug screening, gene functional studies, and biologics production. The market is segmented on the basis of biological source, product service (Upstream and Downstream), and disease indication. Factors such as increasing adoption of advanced technologies for biologic development, favorable environment for clinical trials in developing countries, and an increase in outsourcing of R&D activities are paving way for the growth of the market.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and amalgamation of advanced and specialized technologies. For instance, in February 2020, LakePharma, Inc., and NJ Biopharmaceuticals LLC, a CRO, providing integrated chemistry and biology services, announced a strategic alliance to offer streamlined Antibody-Drug Conjugate (ADC) development solutions for biotechnology and pharmaceutical sectors. Many biopharma and pharma companies are increasingly looking for outsourcing their activities as it helps accelerate workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development and manufacturing organization market growth in the coming years.

Biologics Contract Development Market Report Highlights

·         Mammalian source emerged as the largest product segment in 2019, as the majority of research activities are being carried out using mammalian cell lines

·         The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs)

·         North America dominated the market in 2019. Increase in strategic acquisitions and partnerships and rise in demand for specialized testing services are likely to have a positive impact on the market

·         In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period.

Biologics Contract Development Market Segmentation

Grand View Research has segmented the global biologics contract development market on the basis of source, product service type, disease indication, and region:

Biologics Contract Development Source Outlook (Revenue, USD Million, 2016 - 2027)

·         Microbial

·         Mammalian

·         Others

Browse Details of Report @

Biologics Contract Development Product Service Type Outlook (Revenue, USD Million, 2016 - 2027)

·         Cell Line Development

o    Microbial

o    Mammalian

o    Others

·         Process Development

o    Upstream

o  Microbial

o  Mammalian

o  Others

o    Downstream

o  Impurity, isolation, & identification

o  Physicochemical characterization

o  Pharmaceutical analysis

o  Others

o    By Product

o  MABs

o  Recombinant proteins

o  Others

o    Others

Biologics Contract Development Disease Indication Outlook (Revenue, USD Million, 2016 - 2027)

·         Oncology

·         Immunological disorders

·         Cardiovascular disorders

·         Hematological disorders

·         Others

blog comments powered by Disqus è un servizio offerto da Factotum Srl